MedTrace Logo

Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis

NCT00760968 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2010-06-11

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of TAK-783, once daily (QD), taken in combination with methotrexate in subjects with rheumatoid arthritis.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

TAK-783 and methotrexate

TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.

DRUG

Methotrexate

TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Czechia
  • Latvia
  • Romania
  • Russia
  • Slovakia
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760968 on ClinicalTrials.gov